328233-18-7 Usage
General Description
Trans-3'-Oxo-spiro[cyclohexane-1,1'(3'H)-furo[3,4-c]pyridine]-4-carboxylic acid is a chemical compound with a complex molecular structure. It is a spiro compound, containing a spirocyclic core with a furo[3,4-c]pyridine ring system. The presence of a cyclohexane and carboxylic acid group further adds to the complexity of its structure. trans-3'-Oxo-spiro[cyclohexane-1,1'(3'H)-furo[3,4-c]pyridine]-4-carboxylic acid may have potential use in medicinal chemistry, as the spirocyclic structures are often found in bioactive molecules, and the carboxylic acid group can serve as a handle for further functionalization. The unique structure of trans-3'-Oxo-spiro[cyclohexane-1,1'(3'H)-furo[3,4-c]pyridine]-4-carboxylic acid makes it an interesting target for chemical synthesis and further study in the field of organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 328233-18-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,2,8,2,3 and 3 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 328233-18:
(8*3)+(7*2)+(6*8)+(5*2)+(4*3)+(3*3)+(2*1)+(1*8)=127
127 % 10 = 7
So 328233-18-7 is a valid CAS Registry Number.
328233-18-7Relevant articles and documents
Discovery of trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1′-cyclohexane]-4′-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist
Haga, Yuji,Sakamoto, Toshihiro,Shibata, Takunobu,Nonoshita, Katsumasa,Ishikawa, Makoto,Suga, Takuya,Takahashi, Hirobumi,Takahashi, Toshiyuki,Takahashi, Hidekazu,Ando, Makoto,Murai, Takashi,Gomori, Akira,Oda, Zenjun,Kitazawa, Hidefumi,Mitobe, Yuko,Kanesaka, Maki,Ohe, Tomoyuki,Iwaasa, Hisashi,Ishii, Yasuyuki,Ishihara, Akane,Kanatani, Akio,Fukami, Takehiro
experimental part, p. 6971 - 6982 (2010/02/28)
A series of trans-3-oxospiro[(aza)isobenzofuran-1(3H),1′-cyclohexane]-4′-carboxamide derivatives were synthesized to identify potent NPY Y5 receptor antagonists. Of the compounds, 21j showed high Y5 binding affinity, metabolic stability and brain and cerebrospinal fluid (CSF) penetration, and low susceptibility to P-glycoprotein transporters. Oral administration of 21j significantly inhibited the Y5 agonist-induced food intake in rats with a minimum effective dose of 1 mg/kg. This compound was selected for proof-of-concept studies in human clinical trials.
